KAT14

Summary

KAT14 (lysine acetyltransferase 14, HGNC:15904) is a protein-coding gene on chromosome 20p11.23, encoding Cysteine-rich protein 2-binding protein (Q9H8E8). Component of the ATAC complex, a complex with histone acetyltransferase activity on histones H3 and H4.

CSRP2 is a protein containing two LIM domains, which are double zinc finger motifs found in proteins of diverse function. CSRP2 and some related proteins are thought to act as protein adapters, bridging two or more proteins to form a larger protein complex. The protein encoded by this gene binds to one of the LIM domains of CSRP2 and contains an acetyltransferase domain. Although the encoded protein has been detected in the cytoplasm, it is predominantly a nuclear protein. Alternatively spliced transcript variants have been described.

Source: NCBI Gene 57325 — RefSeq curated summary.

At a glance

• Gene–disease (curated): multiple congenital anomalies/dysmorphic syndrome (Limited, GenCC)
• GWAS associations: 2
• Clinical variants (ClinVar): 53 total — 2 likely-pathogenic
• MANE Select transcript: NM_001392073

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:15904
Approved symbol	KAT14
Name	lysine acetyltransferase 14
Location	20p11.23
Locus type	gene with protein product
Status	Approved
Aliases	CRP2BP, dJ717M23.1, PRO1194, ATAC2
Ensembl gene	ENSG00000149474
Ensembl biotype	protein_coding
OMIM	617501
Entrez	57325

Gene structure

Transcript identifiers

Ensembl transcripts: 13 — 10 protein_coding, 3 nonsense_mediated_decay

ENST00000377681, ENST00000435364, ENST00000464792, ENST00000489634, ENST00000676935, ENST00000676992, ENST00000677174, ENST00000677266, ENST00000677573, ENST00000677610, ENST00000678772, ENST00000678777, ENST00000688188

RefSeq mRNA: 15 — MANE Select: NM_001392073 NM_001384192, NM_001392069, NM_001392070, NM_001392071, NM_001392072, NM_001392073, NM_001392074, NM_001392075, NM_001392076, NM_001392077, NM_001392078, NM_001392079, NM_001392080, NM_001392081, NM_020536

CCDS: CCDS13133, CCDS93011

Canonical transcript exons

ENST00000688188 — 11 exons

Exon	Start	End
ENSE00000859280	18145233	18145351
ENSE00000859284	18162377	18162945
ENSE00000859285	18181710	18181846
ENSE00000859286	18183123	18183298
ENSE00000859287	18184602	18184792
ENSE00001474844	18161823	18162239
ENSE00001734123	18159084	18159265
ENSE00001861002	18142208	18142919
ENSE00003516923	18150821	18150942
ENSE00003924246	18137863	18138051
ENSE00003937364	18187286	18188035

Expression profiles

Bgee: expression breadth ubiquitous, 247 present calls, max score 91.22.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 2.1011 / max 76.3783, expressed in 1060 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
183676	14.3814	1773
183677	4.3706	1628
183678	1.7182	1050
183680	0.3088	30
183681	0.0585	25
183679	0.0157	9

Top tissues by expression

255 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
deltoid	UBERON:0001476	91.22	gold quality
kidney epithelium	UBERON:0004819	90.80	silver quality
quadriceps femoris	UBERON:0001377	90.51	gold quality
vastus lateralis	UBERON:0001379	90.42	gold quality
upper arm skin	UBERON:0004263	90.42	gold quality
cardiac muscle of right atrium	UBERON:0003379	90.16	silver quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	89.29	gold quality
left ventricle myocardium	UBERON:0006566	89.21	silver quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	88.55	gold quality
skeletal muscle tissue	UBERON:0001134	88.42	gold quality
biceps brachii	UBERON:0001507	88.22	gold quality
muscle tissue	UBERON:0002385	88.01	gold quality
tibialis anterior	UBERON:0001385	87.99	silver quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	87.11	gold quality
muscle of leg	UBERON:0001383	86.91	gold quality
gastrocnemius	UBERON:0001388	86.91	gold quality
hindlimb stylopod muscle	UBERON:0004252	86.74	gold quality
myocardium	UBERON:0002349	86.09	silver quality
cortical plate	UBERON:0005343	85.72	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	85.23	gold quality
lateral globus pallidus	UBERON:0002476	85.20	gold quality
lateral nuclear group of thalamus	UBERON:0002736	84.92	gold quality
substantia nigra pars compacta	UBERON:0001965	84.52	gold quality
prefrontal cortex	UBERON:0000451	84.40	gold quality
jejunum	UBERON:0002115	84.23	gold quality
islet of Langerhans	UBERON:0000006	84.13	gold quality
ventricular zone	UBERON:0003053	83.78	gold quality
superior frontal gyrus	UBERON:0002661	83.72	gold quality
ganglionic eminence	UBERON:0004023	83.66	gold quality
postcentral gyrus	UBERON:0002581	83.59	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	4.55

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

39 targeting KAT14, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-MIR-19A-3P	99.98	75.33	2762
HSA-MIR-19B-3P	99.98	75.44	2754
HSA-MIR-545-3P	99.95	70.74	2783
HSA-MIR-515-5P	99.92	69.82	2343
HSA-MIR-519E-5P	99.92	69.62	2358
HSA-MIR-548AJ-5P	99.78	71.12	3085
HSA-MIR-548F-5P	99.78	71.02	3093
HSA-MIR-548G-5P	99.78	71.12	3085
HSA-MIR-548X-5P	99.78	71.12	3085
HSA-MIR-12130	99.75	65.47	452
HSA-MIR-148A-3P	99.74	73.77	1700
HSA-MIR-148B-3P	99.74	73.75	1700
HSA-MIR-152-3P	99.74	73.75	1703
HSA-MIR-5093	99.67	69.26	2291
HSA-MIR-4756-3P	99.62	66.30	1319
HSA-MIR-4677-3P	99.49	67.91	1246
HSA-MIR-208A-5P	99.42	70.83	1913
HSA-MIR-208B-5P	99.42	70.83	1952
HSA-MIR-5580-5P	99.38	66.96	1139
HSA-MIR-3199	99.17	65.19	696
HSA-MIR-8052	99.17	65.01	719
HSA-MIR-4705	99.10	69.10	1091
HSA-MIR-6506-5P	99.04	65.66	1386
HSA-MIR-3190-5P	98.87	64.89	1345
HSA-MIR-34B-3P	98.70	67.40	1171
HSA-MIR-92A-1-5P	98.28	64.51	631
HSA-MIR-6870-3P	98.08	65.10	692
HSA-MIR-4294	97.86	65.72	1110
HSA-MIR-146B-3P	97.83	65.29	782

Literature-anchored findings (GeneRIF, showing 2)

• Actin binds directly to the hATAC subunit KAT14, and modulates its histone acetyl transferase activity in vitro and in cells. (PMID:30890647)
• Lysine acetyltransferase 14 mediates TGF-beta-induced fibrosis in ovarian endometrioma via co-operation with serum response factor. (PMID:38867256)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	kat14	ENSDARG00000041708
mus_musculus	Kat14	ENSMUSG00000027425
rattus_norvegicus	Kat14	ENSRNOG00000007160
drosophila_melanogaster	Atac2	FBGN0032691

Protein

Protein identifiers

Cysteine-rich protein 2-binding protein — Q9H8E8 (reviewed: Q9H8E8)

Alternative names: ADA2A-containing complex subunit 2, CRP2-binding partner, Lysine acetyltransferase 14

All UniProt accessions (6): A0A075B6H4, A0A7I2V3N1, A0A7I2V456, Q9H8E8, A0A7I2V574, D6RAU4

UniProt curated annotations — full annotation on UniProt →

Function. Component of the ATAC complex, a complex with histone acetyltransferase activity on histones H3 and H4. May function as a scaffold for the ATAC complex to promote ATAC complex stability. Has also weak histone acetyltransferase activity toward histone H4. Required for the normal progression through G1 and G2/M phases of the cell cycle.

Subunit / interactions. Interacts with the LIM 1 domain of CSRP2. Component of the ADA2A-containing complex (ATAC), composed of CSRP2BP, KAT2A, TADA2L, TADA3L, ZZ3, MBIP, WDR5, YEATS2, CCDC101 and DR1. In the complex, it probably interacts directly with KAT2A, MBIP and WDR5.

Subcellular location. Nucleus. Cytoplasm.

Tissue specificity. Expressed in skeletal muscle, heart, lung, placenta, brain, liver, pancreas and kidney. High expression in skeletal muscle and heart. Lower expression in lung.

Miscellaneous. May be due to an intron retention.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9H8E8-1	1	yes
Q9H8E8-2	2

RefSeq proteins (15): NP_001371121, NP_001378998, NP_001378999, NP_001379000, NP_001379001, NP_001379002, NP_001379003, NP_001379004, NP_001379005, NP_001379006, NP_001379007, NP_001379008, NP_001379009, NP_001379010, NP_065397 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000182	GNAT_dom	Domain
IPR016181	Acyl_CoA_acyltransferase	Homologous_superfamily

Pfam: PF00583

Enzyme classification (BRENDA):

• EC 2.3.1.48 — histone acetyltransferase (BRENDA: 41 organisms, 681 substrates, 1134 inhibitors, 140 Km, 96 kcat entries)

Substrate kinetics (BRENDA)

27 substrates with measured Km, best-characterized 15. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
ACETYL-COA	0.0002–0.046	51
HISTONE H3	0.007–2.09	23
HISTONE H4	—	11
HISTONE H4 PEPTIDE	0.0208–0.197	7
HISTONE	0.075–1.4	6
HISTONE H3 TAIL PEPTIDE	0.044–0.112	4
PICCOLONUA4 PEPTIDE	0.135–0.372	4
3-AZIDOPROPIONYL-COA	0.0002–0.0086	3
4-PENTYNOYL-COA	0.0009–0.0859	3
SPERMIDINE	0.18–0.27	3
5-HEXYNOYL-COA	0.0006–0.0117	2
6-HEPTYNOYL-COA	0.0003–0.0237	2
HISTONE H3-PEPTIDE	0.05–0.49	2
PROTEIN P53	1.28–4.63	2
3-AZIDOPROPANOYL-COA	0.0103	1

UniProt features (22 total): modified residue 5, sequence variant 5, region of interest 4, compositionally biased region 4, chain 1, domain 1, splice variant 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9H8E8-F1	67.36	0.26

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (5): 4, 231, 285, 292, 416

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-3214847	HATs acetylate histones
R-HSA-9772755	Formation of WDR5-containing histone-modifying complexes

MSigDB gene sets: 137 (showing top): GOBP_REGULATION_OF_PROTEIN_DEACETYLATION, GOBP_MACROMOLECULE_DEACYLATION, WEI_MYCN_TARGETS_WITH_E_BOX, WANG_LMO4_TARGETS_DN, TGCTGAY_UNKNOWN, GOBP_REGULATION_OF_CELL_CYCLE, USF_01, GOBP_REGULATION_OF_CELL_DIVISION, ZHOU_INFLAMMATORY_RESPONSE_LIVE_DN, IK2_01, GOBP_EMBRYO_DEVELOPMENT, GOBP_REGULATION_OF_EMBRYONIC_DEVELOPMENT, GOBP_CHROMATIN_REMODELING, GOCC_SPINDLE, TGGAAA_NFAT_Q4_01

GO Biological Process (8): negative regulation of transcription by RNA polymerase II (GO:0000122), regulation of DNA-templated transcription (GO:0006355), regulation of transcription by RNA polymerase II (GO:0006357), regulation of embryonic development (GO:0045995), regulation of cell division (GO:0051302), regulation of cell cycle (GO:0051726), G2/M transition of mitotic cell cycle (GO:0000086), chromatin remodeling (GO:0006338)

GO Molecular Function (4): histone acetyltransferase activity (GO:0004402), LIM domain binding (GO:0030274), protein binding (GO:0005515), acyltransferase activity, transferring groups other than amino-acyl groups (GO:0016747)

GO Cellular Component (5): nucleus (GO:0005634), nucleoplasm (GO:0005654), cytoplasm (GO:0005737), mitotic spindle (GO:0072686), ATAC complex (GO:0140672)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Chromatin modifying enzymes	1
Epigenetic regulation by WDR5-containing histone modifying complexes	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
transcription by RNA polymerase II	2
regulation of cellular process	2
cellular anatomical structure	2
regulation of transcription by RNA polymerase II	1
negative regulation of DNA-templated transcription	1
DNA-templated transcription	1
regulation of gene expression	1
regulation of RNA biosynthetic process	1
regulation of DNA-templated transcription	1
embryo development	1
regulation of multicellular organismal development	1
cell division	1
cell cycle	1
mitotic cell cycle	1
mitotic cell cycle phase transition	1
cell cycle G2/M phase transition	1
chromatin organization	1
protein-lysine-acetyltransferase activity	1
histone modifying activity	1
protein domain specific binding	1
binding	1
acyltransferase activity	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
intracellular anatomical structure	1
spindle	1
SAGA-type complex	1

Protein interactions and networks

STRING

998 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
KAT14	ZZZ3	Q8IYH5	898
KAT14	YEATS2	Q9ULM3	821
KAT14	KAT2B	Q92831	810
KAT14	SGF29	Q96ES7	772
KAT14	KAT2A	Q92830	771
KAT14	TADA2B	Q86TJ2	691
KAT14	TADA2A	O75478	668
KAT14	DR1	Q01658	631
KAT14	NAA20	P61599	584
KAT14	TADA3	O75528	571
KAT14	TAF6	P49848	524
KAT14	ZNF250	P15622	500
KAT14	TAF5	Q15542	485
KAT14	TFIP11	Q9UBB9	467
KAT14	SUPT20H	Q8NEM7	464

IntAct

106 interactions, top by confidence:

A	B	Type	Score
PSMC3	PSMD9	psi-mi:“MI:0914”(association)	0.940
WDR5	KMT2D	psi-mi:“MI:0914”(association)	0.910
KAT14	MBIP	psi-mi:“MI:0915”(physical association)	0.860
MBIP	KAT14	psi-mi:“MI:0915”(physical association)	0.860
CDK8	MED19	psi-mi:“MI:2364”(proximity)	0.850
SGF29	NDC80	psi-mi:“MI:0914”(association)	0.840
TADA3	TADA2A	psi-mi:“MI:0914”(association)	0.740
TRIM27	KAT14	psi-mi:“MI:0915”(physical association)	0.720
KAT14	TRIM27	psi-mi:“MI:0915”(physical association)	0.720
WDR5	MEN1	psi-mi:“MI:0914”(association)	0.710
HSPB2	BAG3	psi-mi:“MI:0914”(association)	0.670
PSMC3	PSMD12	psi-mi:“MI:0914”(association)	0.640
KAT14	MBIP	psi-mi:“MI:0915”(physical association)	0.560
MBIP	KAT14	psi-mi:“MI:0915”(physical association)	0.560
KAT14	SERTAD1	psi-mi:“MI:0915”(physical association)	0.560
TRIM54	KAT14	psi-mi:“MI:0915”(physical association)	0.560
CEP70	KAT14	psi-mi:“MI:0915”(physical association)	0.560
ZFY	KAT14	psi-mi:“MI:0915”(physical association)	0.560
DPPA4	KAT14	psi-mi:“MI:0915”(physical association)	0.560
MAGEA10	POTEF	psi-mi:“MI:0914”(association)	0.530
FHL2	CNOT1	psi-mi:“MI:0914”(association)	0.530

BioGRID (178): CSRP2BP (Two-hybrid), CSRP2BP (Two-hybrid), CSRP2BP (Affinity Capture-MS), HIST1H3A (Biochemical Activity), HIST1H4A (Biochemical Activity), CSRP2BP (Affinity Capture-MS), CSRP2BP (Affinity Capture-MS), CSRP2BP (Affinity Capture-MS), CSRP2BP (Affinity Capture-MS), CSRP2BP (Affinity Capture-MS), CSRP2BP (Affinity Capture-MS), CSRP2BP (Affinity Capture-MS), CSRP2BP (Affinity Capture-MS), CSRP2BP (Affinity Capture-MS), CSRP2BP (Two-hybrid)

ESM2 similar proteins: A0A5F9C6I2, A1L3F5, A2BDA5, A3KGS3, A8E4X8, D3ZXK7, F1R7R1, O75129, P21359, P51593, P97526, Q04690, Q1JPG0, Q2PPJ7, Q3SZD5, Q4QQM5, Q4R5A4, Q5RC14, Q5XPI3, Q5XPI4, Q62717, Q66K64, Q6GLR7, Q6NXD8, Q6P4S8, Q6PFH3, Q6VNB8, Q7L4E1, Q7TMY8, Q7Z6Z7, Q80TJ1, Q86UW7, Q8BHR8, Q8BK03, Q8BYR5, Q8CDG3, Q8CF97, Q8CID0, Q8IY22, Q8IZQ1

Diamond homologs: O43189, Q02395, Q24459, Q5R7T9, Q5T6S3, Q8CID0, Q9CXG9, Q9H8E8, Q9Y483, Q9Z1B8, O60070, Q6IE82, Q7YZH1, Q7ZVP1, Q92613

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 110 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Formation of WDR5-containing histone-modifying complexes	10	33.2×	1e-10
Epigenetic regulation by WDR5-containing histone modifying complexes	9	17.4×	5e-07
Proteasome assembly	5	12.8×	3e-03
Epigenetic regulation of gene expression	10	8.9×	3e-05
HATs acetylate histones	9	8.9×	9e-05
Chromatin organization	8	8.2×	6e-04
MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis	7	7.2×	3e-03
Chromatin modifying enzymes	8	7.2×	1e-03

GO biological processes:

GO term	Partners	Fold	FDR
regulation of cell division	7	50.6×	2e-08
regulation of embryonic development	9	28.1×	2e-08
regulation of DNA repair	5	13.0×	3e-03
regulation of cell cycle	11	7.7×	2e-05

Disease & clinical

Clinical variants and AI predictions

ClinVar

53 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	2
Uncertain significance	19
Likely benign	3
Benign	1

Top pathogenic / likely-pathogenic (2)

Variant ID	HGVS	Classification
402155	NM_001392073.1(KAT14):c.1396G>A (p.Glu466Lys)	Likely pathogenic
981504	NM_001164811.2(PET117):c.172C>T (p.Gln58Ter)	Likely pathogenic

SpliceAI

2234 predictions. Top by Δscore:

Variant	Effect	Δscore
20:18142202:TTTTA:T	acceptor_loss	1.0000
20:18142203:TTTA:T	acceptor_loss	1.0000
20:18142204:TTA:T	acceptor_loss	1.0000
20:18142205:TA:T	acceptor_loss	1.0000
20:18142206:A:AG	acceptor_gain	1.0000
20:18142206:AG:A	acceptor_loss	1.0000
20:18142206:AGAG:A	acceptor_gain	1.0000
20:18142207:G:GG	acceptor_gain	1.0000
20:18142207:GA:G	acceptor_gain	1.0000
20:18142207:GAGG:G	acceptor_gain	1.0000
20:18142207:GAGGC:G	acceptor_gain	1.0000
20:18142916:GCCA:G	donor_gain	1.0000
20:18142920:G:GG	donor_gain	1.0000
20:18150936:GGAA:G	donor_gain	1.0000
20:18183112:T:TA	acceptor_gain	1.0000
20:18184793:G:GG	donor_gain	1.0000
20:18187284:A:AG	acceptor_gain	1.0000
20:18187285:G:GG	acceptor_gain	1.0000
20:18138047:AGCAG:A	donor_loss	0.9900
20:18138048:GCAG:G	donor_gain	0.9900
20:18138049:CAGGT:C	donor_loss	0.9900
20:18138051:GGTC:G	donor_loss	0.9900
20:18138052:GTCG:G	donor_loss	0.9900
20:18138053:T:G	donor_loss	0.9900
20:18145348:GCAA:G	donor_gain	0.9900
20:18145352:G:GG	donor_gain	0.9900
20:18150937:GAA:G	donor_gain	0.9900
20:18181708:A:AG	acceptor_gain	0.9900
20:18181709:G:GG	acceptor_gain	0.9900
20:18181843:TCAG:T	donor_loss	0.9900

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000048126 (20:18160791 A>C,G), RS1000079257 (20:18148966 A>G), RS1000126740 (20:18167635 T>A), RS1000150140 (20:18177897 A>T), RS1000153774 (20:18186533 A>G), RS1000172629 (20:18179658 C>T), RS1000229768 (20:18186274 G>A,T), RS1000266278 (20:18167192 G>T), RS1000286344 (20:18174961 G>A), RS1000327560 (20:18173686 A>T), RS1000376615 (20:18137270 T>A,C), RS1000407681 (20:18137489 G>C), RS1000585863 (20:18155921 A>G), RS1000683662 (20:18143684 A>G), RS1000778846 (20:18149156 G>A,T)

Disease associations

OMIM: gene MIM:617501 | disease phenotypes: MIM:619063

GenCC curated gene-disease

Disease	Classification	Inheritance
multiple congenital anomalies/dysmorphic syndrome	Limited	Autosomal recessive

Mondo (2): mitochondrial complex IV deficiency, nuclear type 19 (MONDO:0033654), multiple congenital anomalies/dysmorphic syndrome (MONDO:0019042)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST000873_2	Anorexia nervosa	2.000000e-06
GCST008170_4	Thyroglobulin plasma levels	3.000000e-06

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0010050	thyroglobulin measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

48 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	affects cotreatment, increases expression	3
sodium arsenite	decreases expression	3
Hydrogen Peroxide	affects expression, increases expression	2
Cyclosporine	decreases expression	2
aristolochic acid I	increases expression	1
FR900359	increases phosphorylation	1
methylmercuric chloride	decreases expression	1
triphenyl phosphate	affects expression	1
pirinixic acid	increases expression, affects binding, increases activity	1
beta-lapachone	decreases expression, increases expression	1
arsenite	increases methylation	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
ochratoxin A	decreases expression	1
potassium chromate(VI)	affects cotreatment, decreases expression	1
ferrous chloride	decreases expression	1
nickel sulfate	decreases expression	1
epigallocatechin gallate	affects cotreatment, decreases expression	1
di-n-butylphosphoric acid	affects expression	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
abrine	decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
jinfukang	affects cotreatment, increases expression	1
Temozolomide	increases expression	1
Acetaminophen	decreases expression	1
Benzo(a)pyrene	decreases expression	1
Cisplatin	affects cotreatment, increases expression	1
Dexamethasone	affects cotreatment, increases expression	1
Succimer	affects cotreatment, decreases expression	1
Dimethyl Sulfoxide	increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.